JP2021523912A5 - - Google Patents

Info

Publication number
JP2021523912A5
JP2021523912A5 JP2020564152A JP2020564152A JP2021523912A5 JP 2021523912 A5 JP2021523912 A5 JP 2021523912A5 JP 2020564152 A JP2020564152 A JP 2020564152A JP 2020564152 A JP2020564152 A JP 2020564152A JP 2021523912 A5 JP2021523912 A5 JP 2021523912A5
Authority
JP
Japan
Prior art keywords
peptide
delivery vehicle
composition according
mucus
permeable
Prior art date
Application number
JP2020564152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523912A (ja
JPWO2019222400A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/032484 external-priority patent/WO2019222400A2/en
Publication of JP2021523912A publication Critical patent/JP2021523912A/ja
Publication of JP2021523912A5 publication Critical patent/JP2021523912A5/ja
Publication of JPWO2019222400A5 publication Critical patent/JPWO2019222400A5/ja
Withdrawn legal-status Critical Current

Links

JP2020564152A 2018-05-15 2019-05-15 粘液透過性ペプチド、送達ビヒクルおよび治療方法 Withdrawn JP2021523912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671709P 2018-05-15 2018-05-15
US62/671,709 2018-05-15
PCT/US2019/032484 WO2019222400A2 (en) 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy

Publications (3)

Publication Number Publication Date
JP2021523912A JP2021523912A (ja) 2021-09-09
JP2021523912A5 true JP2021523912A5 (https=) 2022-05-16
JPWO2019222400A5 JPWO2019222400A5 (https=) 2022-05-16

Family

ID=68540758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564152A Withdrawn JP2021523912A (ja) 2018-05-15 2019-05-15 粘液透過性ペプチド、送達ビヒクルおよび治療方法

Country Status (7)

Country Link
US (1) US20210177982A1 (https=)
EP (1) EP3796892A2 (https=)
JP (1) JP2021523912A (https=)
CN (1) CN112367974A (https=)
AU (1) AU2019269590A1 (https=)
CA (1) CA3100020A1 (https=)
WO (1) WO2019222400A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176111A (en) 1876-04-11 Improvement in car-couplings
EP2253326B1 (en) * 2008-02-28 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2863632C (en) * 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013256064B2 (en) * 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR101669203B1 (ko) * 2014-06-18 2016-10-25 한국과학기술연구원 신규 세포투과성 펩타이드 및 이의 용도
WO2018013907A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
US11090391B2 (en) * 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Similar Documents

Publication Publication Date Title
ES2871029T3 (es) Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos
García‐Fernández et al. New advances in in vivo applications of gated mesoporous silica as drug delivery nanocarriers
JP2021523912A5 (https=)
Ge et al. Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors
Bruno et al. Basics and recent advances in peptide and protein drug delivery
Ding et al. NO-releasing polypeptide nanocomposites reverse cancer multidrug resistance via triple therapies
Yang et al. Drug and gene co-delivery systems for cancer treatment
Bernkop-Schnürch et al. Chitosan-based drug delivery systems
ES2856091T3 (es) Nanoconjugados capaces de atravesar la barrera hematoencefálica
Zou et al. Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery
Afrin et al. Oral delivery of RNAi for cancer therapy
CN110573184B (zh) Rna纳米结构，其制备方法和用途
Garbayo et al. Diagnostic and therapeutic uses of nanomaterials in the brain
Rad et al. Material and design toolkit for drug delivery: state of the art, trends, and challenges
Führmann et al. Peptide-functionalized polymeric nanoparticles for active targeting of damaged tissue in animals with experimental autoimmune encephalomyelitis
JP2020500218A5 (https=)
Chevalier si RNA targeting and treatment of gastrointestinal diseases
Yi et al. Brain delivery of proteins via their fatty acid and block copolymer modifications
Rao et al. Functional stimuli-responsive polymeric network nanogels as cargo systems for targeted drug delivery and gene delivery in cancer cells
Kubiatowicz et al. Nanomedicine for oral delivery: strategies to overcome the biological barriers
JP2026001029A (ja) がん治療のための化学療法剤とα－ラクトアルブミン－オレイン酸複合体の組合せ
CN107998081B (zh) 囊泡纳米药物在制备脑肿瘤治疗药物中的应用
JPWO2019222400A5 (https=)
Meng et al. Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
Zhang et al. Development and advantages of drug delivery systems